Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Asterias and BioTime reverse merge to focus on cancer, neuro cell therapies

Executive Summary

BioTime Inc. is re-acquiring an ownership stake in former subsidiary Asterias Biotherapeutics Inc., resulting in a merged cell therapy company in which Asterias will be the surviving entity and hold 16.2%.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Intra-Biotech Deal
    • Reverse Acquisition
    • Payment Includes Stock
    • Includes Contract

Related Companies